Tower Research Capital LLC TRC Increases Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Tower Research Capital LLC TRC increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 7,944.8% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 6,999 shares of the company's stock after acquiring an additional 6,912 shares during the period. Tower Research Capital LLC TRC's holdings in Krystal Biotech were worth $1,096,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Entropy Technologies LP purchased a new position in shares of Krystal Biotech during the 4th quarter worth approximately $548,000. Janney Montgomery Scott LLC grew its stake in shares of Krystal Biotech by 42.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock valued at $8,239,000 after buying an additional 15,545 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Krystal Biotech by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock valued at $19,340,000 after buying an additional 3,727 shares during the period. abrdn plc lifted its stake in Krystal Biotech by 32.5% during the 4th quarter. abrdn plc now owns 57,033 shares of the company's stock worth $8,935,000 after acquiring an additional 13,979 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after acquiring an additional 433 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. HC Wainwright increased their price target on shares of Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a research report on Monday. Chardan Capital increased their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $222.71.

Krystal Biotech Trading Up 1.0 %

NASDAQ:KRYS traded up $1.67 during trading hours on Monday, hitting $169.73. The company's stock had a trading volume of 167,657 shares, compared to its average volume of 295,598. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34. The stock has a market capitalization of $4.90 billion, a P/E ratio of 56.77 and a beta of 0.75. The stock has a fifty day moving average of $176.37 and a 200-day moving average of $171.56.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business's revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.30 EPS. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).